{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&q=CRPC", "query": { "q": "CRPC", "condition": "Prostate Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 242, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&q=CRPC&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T23:43:03.416Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04363164", "title": "Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration Resistant Metastatic Prostate Cancer" ], "interventions": [ { "name": "Testosterone cypionate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Testosterone enanthate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "MALE", "summary": "18 Years to 90 Years · Male only" }, "enrollment_count": 150, "start_date": "2020-08-19", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-07-23T23:43:03.416Z", "location_count": 6, "location_summary": "San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04363164" }, { "nct_id": "NCT02361086", "title": "A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-resistant Prostate Cancer", "CRPC" ], "interventions": [ { "name": "VT-464: given orally once daily in 28 day cycles", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innocrin Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 21, "start_date": "2014-06", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2019-02-01", "last_synced_at": "2026-07-23T23:43:03.416Z", "location_count": 5, "location_summary": "Tampa, Florida • Omaha, Nebraska • Durham, North Carolina + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Myrtle Beach", "state": "South Carolina" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02361086" }, { "nct_id": "NCT01270880", "title": "Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Hormone-resistant Prostate Cancer", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Hsp90 inhibitor STA-9090", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" }, { "name": "RNA analysis", "type": "GENETIC" }, { "name": "spectrophotometry", "type": "OTHER" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "OTHER", "GENETIC" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 18, "start_date": "2011-01", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2018-09-18", "last_synced_at": "2026-07-23T23:43:03.416Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Detroit, Michigan • Piscataway, New Jersey + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Piscataway", "state": "New Jersey" }, { "city": "Wisconsin Rapids", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01270880" }, { "nct_id": "NCT04478279", "title": "A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Melanoma Stage IV", "Breast Cancer", "Prostate Cancer", "Glioblastoma Multiforme", "GBM", "Brain Cancer", "Metastatic Breast Cancer", "Metastatic Melanoma", "Metastatic Prostate Cancer", "Melanoma Recurrent", "Prostate Cancer Metastatic", "Recurrent Glioblastoma", "Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "ST101", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sapience Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2020-07-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-07-23T23:43:03.416Z", "location_count": 7, "location_summary": "San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Warrenville", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04478279" }, { "nct_id": "NCT04157088", "title": "Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Cancer, Castration-Resistant" ], "interventions": [ { "name": "Darolutamide (Nubeqa, BAY1841788)", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2019-12-17", "completion_date": "2022-07-08", "has_results": true, "last_update_posted_date": "2023-08-04", "last_synced_at": "2026-07-23T23:43:03.416Z", "location_count": 7, "location_summary": "Portland, Maine • Voorhees Township, New Jersey • The Bronx, New York + 4 more", "locations": [ { "city": "Portland", "state": "Maine" }, { "city": "Voorhees Township", "state": "New Jersey" }, { "city": "The Bronx", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Bala-Cynwyd", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04157088" }, { "nct_id": "NCT02793765", "title": "Docetaxel Followed by Provenge in Metastatic Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Sipuleucel-T", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2016-12", "completion_date": "2021-07", "has_results": false, "last_update_posted_date": "2017-10-30", "last_synced_at": "2026-07-23T23:43:03.416Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793765" }, { "nct_id": "NCT01688492", "title": "Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 54, "start_date": "2012-09", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-07-23T23:43:03.416Z", "location_count": 3, "location_summary": "Evanston, Illinois • New York, New York • Portland, Oregon", "locations": [ { "city": "Evanston", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01688492" }, { "nct_id": "NCT01540071", "title": "Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "NRX 194204", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Io Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 38, "start_date": "2011-08", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2021-05-14", "last_synced_at": "2026-07-23T23:43:03.416Z", "location_count": 1, "location_summary": "Fountain Valley, California", "locations": [ { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01540071" }, { "nct_id": "NCT04689828", "title": "177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "68Ga-PSMA-11", "type": "DRUG" }, { "name": "ARDT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 469, "start_date": "2021-06-15", "completion_date": "2026-09-30", "has_results": true, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-23T23:43:03.416Z", "location_count": 20, "location_summary": "Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04689828" }, { "nct_id": "NCT01516866", "title": "Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 58, "start_date": "2011-11", "completion_date": "2018-01-01", "has_results": false, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-07-23T23:43:03.416Z", "location_count": 3, "location_summary": "Bethesda, Maryland • New York, New York • Madison, Wisconsin", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01516866" } ] }